Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05415800 Enrolling by invitation - Cancer Clinical Trials

Quality Improvement Pilot

Start date: April 29, 2022
Phase: N/A
Study type: Interventional

The overall goal of this study is to develop and pilot test the use of practice facilitation as an intervention for healthcare providers and staff, with the goal of improving the implementation of cancer prevention and screening guidelines in primary care settings.

NCT ID: NCT05407844 Enrolling by invitation - Cancer Clinical Trials

Community Health Worker Based Intervention to Improve Palliative Care

DeCIDE-PC
Start date: November 1, 2022
Phase: N/A
Study type: Interventional

The study aims to find out if community health worker (CHW) support will improve palliative care outcomes in African American patients with advanced cancer, by comparing the quality of life of patients who are receiving standard care to those whose standard care is supplemented with CHW support.

NCT ID: NCT05380609 Enrolling by invitation - Cancer Clinical Trials

Accelerated Body Diffusion-Weighted MRI Using Artificial Intelligence

CeleScan-R
Start date: May 6, 2022
Phase:
Study type: Observational

Whole-body diffusion-weighted MRI (WBDWI) is a non-invasive tool used for staging and response evaluation in oncologic practice and is at the core of emerging response criteria in advanced prostate and breast cancers. WBDWI is a sensitive tool that radiologists can use to review the extent of disease and is achieved using a series of sequential imaging stations from the head to the mid-thigh. WBDWI accounts for more than 50% of the acquisition time of conventional whole-body MRI studies with a 1-hour duration. Despite national and international guidance for using whole-body MRI, a recent UK survey indicated that only 27% of UK radiology departments were offering a whole-body MRI service with a lack of scanner availability cited by 50% of respondents as the main challenge to service delivery. In the context of the ever-increasing capacity pressures on MRI departments, reducing acquisition times would facilitate the wider adoption of clinical WBDWI, reduce costs, and improve the patient experience. DWI is also embedded into consensus MRI protocols across almost all tumour types including primary prostate and breast cancers, metastatic liver disease, gynaecological cancers & GI cancers, where acquisition time savings could also be beneficial. The investigators have previously published accelerated DWI with deep learning based denoising filters (quickDWI), which can provide up to 50% reduction in whole-body MRI acquisition times. The goal of the deep-learning algorithm is to remove the noise in these subsampled images, producing an image with acceptable clinical quality. The aim of this investigation is to extend this work by testing quickDWI within a larger retrospective data cohort, incorporating other cancers such as disease of the abdomen and pelvis, primary prostate cancer, liver metastases, and pancreatic cancer.

NCT ID: NCT05256966 Enrolling by invitation - Cancer Clinical Trials

Firefighter Soot, Sauna, and Sweat Excretion Pilot Study

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to evaluate whether sauna use after active-duty firefighting is effective in reducing exposure to certain harmful chemicals called polycyclic aromatic hydrocarbons (PAHs). PAHs are found in soot and several types are known to be carcinogens. This study is a cross-sectional pilot study that will be performed in active-duty firefighters. The firefighters will be subdivided into those who will use a sauna immediately after fighting a fire versus those who will not, the latter of which will serve as a metabolism control group. There will thus be two comparison groups within the study: 1) active-duty firefighters using a sauna after fire suppression (sauna group); 2) active-duty firefighters not using a sauna after fire suppression (metabolism control).

NCT ID: NCT05216380 Enrolling by invitation - Cancer Clinical Trials

Study of Clinic-delivered Physical Activity Referrals to Cancer Survivors

Start date: March 15, 2021
Phase: N/A
Study type: Interventional

Background: Cancer survivors have a greater risk of cardiovascular disease (CVD) and have low physical activity levels. Physical inactivity is one modifiable risk factor for CVD, and increased physical activity has shown a cardioprotective effect on lowering CVD risk. The objective of ActivityLink is to use an electronic referral (e-referral) implementation program for clinic staff to refer survivors to an in-person and a virtual physical activity program. Methods: Participants in this study will include clinic staff and patients. Investigators will first conduct interviews with clinic staff and patients, followed by usability testing of a referral system with staff. The study team will then beta-test two rounds of testing using Plan, Do, Study, Act (PDSA) Cycles for clinic staff to refer patients in the clinic. Quantitative data and qualitative interviews will be collected following each PDSA cycle, with refinements made based on feedback. Outcomes: The proposed study addresses a critical need to implement physical activity referrals into routine cancer survivorship visits.

NCT ID: NCT05080920 Enrolling by invitation - Cancer Clinical Trials

Rosmalip® for Cancer Infections Prevention

OnCOVInf
Start date: October 28, 2020
Phase: N/A
Study type: Interventional

This study is designed to assess the safety and efficacy of Rosmalip® nutritional supplement compared to placebo in subjects with solid cancer for the prevention of infections including COVID-19.

NCT ID: NCT05080907 Enrolling by invitation - Healthy Clinical Trials

Collection and Distribution of Biospecimens for Novel Research

Start date: July 15, 2016
Phase:
Study type: Observational

iSpecimen aims to create a clinical partner network of hospitals, laboratories, academic institutions, and other healthcare organizations ("institutions") capable of providing researchers and educators ("researchers") with annotated biospecimens for use in biomarker discovery and validation; diagnostic test and instrumentation development and validation; therapeutics development; other medical research including the impact that various specimen collection and handling methods and conditions have on research results; and in education such as researcher or physician training (collectively "research").

NCT ID: NCT04877899 Enrolling by invitation - Cancer Clinical Trials

Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol

Start date: October 8, 2020
Phase:
Study type: Observational

This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 dimensional non-contrast resting transthoracic echocardiograms for application in the assessment of patients undergoing chemotherapy with cardiotoxic drugs. This is a single-centre retrospective study which utilizes echocardiographic DICOM image and meta-data datasets received from a Canadian site. Data processed using the AI driven automated processing will be compared to conventionally acquired LVEF and GLS measurements and results will be analysed to determine accuracy and precision.

NCT ID: NCT04867122 Enrolling by invitation - Cancer Clinical Trials

Problem-Solving Therapy for Cancer Caregivers in Outpatient Palliative Care

Start date: January 24, 2022
Phase: N/A
Study type: Interventional

This study is a randomized clinical trial of a problem-solving therapy intervention for family caregivers of individuals with cancer receiving outpatient palliative care.

NCT ID: NCT04852575 Enrolling by invitation - Cancer Clinical Trials

ReVital-CORE Program

ReVital-CORE
Start date: January 25, 2021
Phase:
Study type: Observational [Patient Registry]

Pilot feasibility study of the ReVital Chemotherapy Online Resiliency Evaluation (CORE) program. As part of standard of care, patients starting a new chemotherapy regimen are referred to complete a pre-chemotherapy cancer rehabilitation evaluation (i.e., prehab) and invited to enroll in the ReVital-CORE program study. Once enrolled in ReVital-CORE, participants will complete a monthly online evaluation for 1 year. If frailty (or pre-frailty) is detected on any survey, physical or occupational therapy will be initiated for standard of care rehabilitation evaluation and treatment.